Equities Analysts Offer Predictions for TRDA Q1 Earnings

Entrada Therapeutics, Inc. (NASDAQ:TRDA) – Stock analysts at HC Wainwright lowered their Q1 2025 earnings per share (EPS) estimates for Entrada Therapeutics in a report released on Monday, March 31st. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.92) per share for the quarter, down from their previous estimate of ($0.86). HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Entrada Therapeutics’ current full-year earnings is $1.12 per share. HC Wainwright also issued estimates for Entrada Therapeutics’ Q2 2025 earnings at ($1.00) EPS, Q3 2025 earnings at ($1.06) EPS, Q4 2025 earnings at ($1.12) EPS and FY2025 earnings at ($4.11) EPS.

Entrada Therapeutics (NASDAQ:TRDA) last released its earnings results on Thursday, February 27th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.69. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. The business had revenue of $12.25 million for the quarter, compared to analyst estimates of $11.95 million.

Entrada Therapeutics Trading Down 1.0 %

NASDAQ TRDA opened at $7.94 on Thursday. The company has a market cap of $298.50 million, a price-to-earnings ratio of 4.99 and a beta of -0.14. Entrada Therapeutics has a 1-year low of $7.52 and a 1-year high of $21.79. The company has a 50 day moving average of $11.56 and a 200-day moving average of $15.20.

Institutional Trading of Entrada Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Janus Henderson Group PLC grew its stake in shares of Entrada Therapeutics by 21.6% in the fourth quarter. Janus Henderson Group PLC now owns 2,080,367 shares of the company’s stock worth $36,011,000 after purchasing an additional 368,908 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Entrada Therapeutics by 19.7% during the 4th quarter. Vanguard Group Inc. now owns 1,464,237 shares of the company’s stock worth $25,317,000 after buying an additional 241,052 shares during the period. Geode Capital Management LLC lifted its holdings in Entrada Therapeutics by 8.8% during the 3rd quarter. Geode Capital Management LLC now owns 576,451 shares of the company’s stock worth $9,214,000 after buying an additional 46,512 shares during the period. State Street Corp grew its position in shares of Entrada Therapeutics by 5.5% in the 3rd quarter. State Street Corp now owns 469,601 shares of the company’s stock valued at $7,504,000 after buying an additional 24,385 shares during the last quarter. Finally, Northern Trust Corp increased its stake in shares of Entrada Therapeutics by 28.5% in the fourth quarter. Northern Trust Corp now owns 318,177 shares of the company’s stock valued at $5,501,000 after buying an additional 70,497 shares during the period. 86.39% of the stock is currently owned by institutional investors.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.